Trial Profile
An Open-label Pilot Study to Investigate the Efficacy of Apremilast in the Treatment of Central Centrifugal Cicatricial Alopecia (CCCA)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Apremilast (Primary)
- Indications Alopecia
- Focus Therapeutic Use
- 23 Feb 2021 Status changed from recruiting to completed.
- 26 Sep 2020 Planned End Date changed from 1 Oct 2020 to 1 Mar 2021.
- 26 Sep 2020 Planned primary completion date changed from 1 Oct 2020 to 1 Mar 2021.